<DOC>
	<DOCNO>NCT01745289</DOCNO>
	<brief_summary>The LATTE study extension study close Arimidex , Tamoxifen Alone combination ( ATAC ) trail take place 10 year ago . LATTE aim collect long term follow-up information since conclusion ATAC , least another 5 year , regard : Additional efficacy data ( first local recurrence , first distant recurrence ) , Additional safety data ( ischaemic cardiac cerebrovascular event , fracture ) , Cause specific mortality new primary cancer . The LATTE study pick ATAC leave follow number post-menopausal woman breast cancer randomise receive either anastrozole tamoxifen ATAC Trial know die withdrawn consent April 1st 2009 . Since ATAC nationwide study , woman LATTE also reside receive follow-up care various area country . There vulnerable group participate study . Patient interaction consist person interview designate follow-up time and/or telephone interview . Data collect point contact , whether person clinic site telephone . Telephone interview complete LATTE study office . Topics focus data collection consist : whether suspect recurrence , new breast primary tumour , new primary tumour , ischaemic cardiac event , cerebrovascular event , serious fracture . Since follow-up question short detail , respondent burden time le 1 hour case .</brief_summary>
	<brief_title>Long-term Anastrozole Versus Tamoxifen Treatment Effects</brief_title>
	<detailed_description />
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>patient randomise one monotherapy arm ATAC Trial alive 10 year followup patient withdraw consent participate ATAC Trial study LATTE Executive Committee determine possibility obtain followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Survival</keyword>
	<keyword>Recurrence</keyword>
</DOC>